Company Overview and News

 
Maybank, RHB Bank, Alliance Bank, Media Prima, Utusan Melayu, IGB, AirAsia Group, DiGi.Com, Lafarge Malaysia, Petron Malaysia and Sime Darby

2018-08-30 theedgemarkets
KUALA LUMPUR (Aug 30): Based on corporate announcements and news flow today, stocks in focus on Monday (Sept 3) may include: Malayan Banking Bhd, RHB Bank Bhd, Alliance Bank Malaysia Bhd, Media Prima Bhd, Utusan Melayu (Malaysia) Bhd, IGB Bhd, AirAsia Group Bhd, DiGi.Com, Lafarge Malaysia, Petron Malaysia Refining & Marketing Bhd and Sime Darby Bhd.
4502 1155 5227 5754 MLYBY SMEBF MLYNF MIAHF 4197 BSMAF 3794 1818

 
IGB to directly hold 49% stake in IGB REIT

2018-08-30 theedgemarkets
KUALA LUMPUR (Aug 30): IGB Bhd is undertaking an internal group reorganisation which will see its 49.12% indirect stake in IGB Real Estate Investment Trust (REIT) come directly under the group. Currently the stake is held via wholly-owned IGB Corp Bhd.
5227 BSMAF 1818

 
Stronger y-o-y rental income growth likely for IGB REIT for 3Q

2018-07-19 theedgemarkets
IGB Real Estate Investment Trust (July 18, RM1.74) Maintain buy with an unchanged target price (TP) of RM1.85: IGB Real Estate Investment Trust’s (REIT) second quarter of financial year 2018 (2QFY18) results and second interim net distribution per unit of 2.14 sen (year-to-date: 4.62 sen) were within expectations. Our FY18 to FY20 earnings estimates and dividend discount model-based TP of RM1.85 (cost of equity: 7.
5227

 
Both IGB REIT assets expected to continue to perform well

2018-07-17 theedgemarkets
IGB Real Estate Investment Trust (July 16, RM1.73) Maintain buy with an unchanged target price (TP) of RM1.89: IGB Real Estate Investment Trust’s (REIT) first half year ended June 30, 2018 (1HFY18) revenue of RM264.8 million (+1.4% year-on-year [y-o-y]) translated into a core net profit of RM152.4 million (+6.5% y-o-y). The results were within both our and consensus expectations, accounting for 47.
5227

 
Maybank Investment remains positive on IGB REIT’s resilient earnings

2018-07-17 thestar.com.my
The research house maintained its FY18-20 earnings estimates and target price of RM1.85, while stating that IGB REIT remained its preferred retail REIT pick.
5227

 
Maybank, RHB positive on IGB REIT

2018-07-16 theedgemarkets
KUALA LUMPUR (July 16): Maybank Investment Bank (Maybank IB) Research has maintained IGB Real Estate Investment Trust (IGB REIT) as its preferred retail REIT pick on second quarter 2018 (2Q18) earnings which were within expectations.
5227

 
Research firms positive on IGB REIT

2018-07-16 malaymail
KUALA LUMPUR, July 16 — Maybank Investment Bank (Maybank IB) Research has maintained IGB Real Estate Investment Trust (IGB REIT) as its preferred retail REIT pick on second quarter 2018 (2Q18) earnings which were within expectations.
5227

 
IGB REIT seen to gain from improved consumer sentiment, spending

2018-07-13 theedgemarkets
IGB Real Estate Investment Trust (REIT) (July 12, RM1.66) Maintain buy with an unchanged target price (TP) of RM1.85: IGB REIT sustained its malls’ high occupancy rates with Mid Valley Megamall and The Gardens Mall achieving committed occupancy of circa 100% respectively as at end of first half of 2018 (1H18)
5227

5
Trading ideas: IGB Reit, TNB, Axis Reit, Priceworth, Cycle & Carriage

2018-04-24 thestar.com.my
KUALA LUMPUR: IGB Real Estate Investment Trust (Reit), Tenaga Nasional Bhd (TNB), Axis Reit, Priceworth International Bhd and Cycle & Carriage Bintang Bhd are among the stocks to watch, according to JF Apex Research.
5227 5347 TNABY TNABF 7123

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...